Title: Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness.
Journal: Experimental gerontology 20120801
Title: Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
Journal: Diabetes 20120801
Title: Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats.
Journal: International journal of impotence research 20120101
Title: Renoprotective antioxidant effect of alagebrium in experimental diabetes.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101
Title: The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
Journal: Rejuvenation research 20110801
Title: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.
Journal: European journal of heart failure 20110801
Title: Targeted reduction of advanced glycation improves renal function in obesity.
Journal: Kidney international 20110701
Title: Does accumulation of advanced glycation end products contribute to the aging phenotype?
Journal: The journals of gerontology. Series A, Biological sciences and medical sciences 20100901
Title: Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Journal: American journal of physiology. Renal physiology 20100301
Title: Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.
Journal: European journal of heart failure 20100301
Title: Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.
Journal: British journal of pharmacology 20100101
Title: Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage.
Journal: Transactions of the American Ophthalmological Society 20091201
Title: Alagebrium chloride protects the heart against oxidative stress in aging rats.
Journal: The journals of gerontology. Series A, Biological sciences and medical sciences 20090601
Title: Letter by Hartog et al. regarding article, 'Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines'.
Journal: Circulation 20090317
Title: Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
Journal: Circulation 20080902
Title: Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.
Journal: American journal of physiology. Endocrinology and metabolism 20080801
Title: Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Journal: Diabetologia 20080601
Title: Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?
Journal: Annals of the New York Academy of Sciences 20080401
Title: Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080301
Title: Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.
Journal: Diabetologia 20070801
Title: Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
Journal: Kidney international. Supplement 20070801
Title: Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Journal: Journal of hypertension 20070301
Title: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Journal: Endocrinology 20070201
Title: Alagebrium: benefit on peripheral arteries.
Journal: Journal of cardiac failure 20060901
Title: The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment.
Journal: The journal of sexual medicine 20060301
Title: Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
Journal: American journal of nephrology 20060101
Title: [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601
Title: [Development of therapeutic agents for diabetic neuropathies].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601
Title: Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Journal: Annals of the New York Academy of Sciences 20050601
Title: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
Journal: Journal of cardiac failure 20050401
Title: The next generation of diabetic nephropathy therapies: an update.
Journal: Advances in chronic kidney disease 20050401
Title: [Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20050101
Title: Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
Journal: American journal of hypertension 20041201
Title: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
Journal: American journal of hypertension 20041201
Title: Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Journal: Diabetes 20041101
Title: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Journal: Journal of the American Society of Nephrology : JASN 20040801
Title: Crosslink breakers: a new approach to cardiovascular therapy.
Journal: Current opinion in cardiology 20040701
Title: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Journal: Diabetes 20040701
Title: Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
Journal: American journal of hypertension 20040401
Title: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
Journal: American journal of physiology. Heart and circulatory physiology 20031201
Title: Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Journal: Archives of biochemistry and biophysics 20031101
Title: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
Journal: Archives of biochemistry and biophysics 20031101
Title: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030901
Title: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Journal: Circulation research 20030418
Title: [Aminoguanidine and other AGE inhibitors].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20020901
Title: Glucose-mediated cross-linking of collagen in rat tendon and skin.
Journal: Clinica chimica acta; international journal of clinical chemistry 20020701
Title: Protein glycation, diabetes, and aging.
Journal: Recent progress in hormone research 20010101
Title: Watson AM, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGEactivation in diabetic apolipoprotein E knockout mice. Diabetes. 2012 Aug;61(8):2105-13.
Title: Wang H, et al. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am J Physiol Heart Circ Physiol. 2015 Oct;309(7):H1130-40.
